To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based enzyme-linked immunosorbent assay (ELISA) for use with saliva samples, achieving 84.2% sensitivity and 100% specificity in a set of 149 clinical samples. This strategy will enable widespread, affordable testing for patients who experienced this disease, whilst minimizing exposure risk for healthcare workers.
All Keywords
【저자키워드】 viral infection, Diagnostic markers, ELISA, 【초록키워드】 Saliva, Antibody testing, Healthcare workers, COVID-19 pandemic, risk, clinical samples, serum, sensitivity, specificity, enzyme-linked immunosorbent assay, healthcare, Patient, United States, disease, Containment, Non-invasive, saliva samples, widespread, enzyme-linked immunosorbent, the United State, required, facilitate, 【제목키워드】 Saliva, SARS-CoV-2 antibody,
【저자키워드】 viral infection, Diagnostic markers, ELISA, 【초록키워드】 Saliva, Antibody testing, Healthcare workers, COVID-19 pandemic, risk, clinical samples, serum, sensitivity, specificity, enzyme-linked immunosorbent assay, healthcare, Patient, United States, disease, Containment, Non-invasive, saliva samples, widespread, enzyme-linked immunosorbent, the United State, required, facilitate, 【제목키워드】 Saliva, SARS-CoV-2 antibody,
현재 미국과 전 세계에서 활동 중인 COVID-19 대유행의 억제를 용이하게 하려면 손쉬운 비침습적 항체 검사 옵션이 필요합니다. 여기에서 우리는 타액 샘플과 함께 사용하기 위해 상업적으로 이용 가능한 혈청 기반 효소 결합 면역흡착 분석법(ELISA)을 채택하여 149개의 임상 샘플 세트에서 84.2% 감도와 100% 특이성을 달성했습니다. 이 전략은 의료 종사자의 노출 위험을 최소화하면서 이 질병을 경험한 환자를 위한 광범위하고 저렴한 테스트를 가능하게 할 것입니다.